PeopleBeatingCancer

Ivermectin and Breast Cancer Metastasis

Share Button

Ivermectin and Breast Cancer Metastasis- Metastasis Drives Most Cancer Deaths. Approximately 90% of cancer deaths are related to metastasis, not the original tumor. Researchers are therefore investigating whether ivermectin might influence metastatic pathways.

My name is David Emerson. I was diagnosed with an incurable blood cancer called multiple myeloma in early 1994. After undergoing aggressive standard-of-care therapies for my cancer, I relapsed and was told that “nothing more could be done for me.”  My oncologist told me that in September of 1997.

I underwent a non-FDA-approved therapy that put me in complete remission from my incurable cancer. I have only sympathy for cancer patients looking for therapies that work.

My goal is to make sure that breast cancer patients and survivors who consider ivermectin understand the risks and benefits of this therapy.

If you’d like to learn more about repurposed drugs and cancer treatment, click now. 

Thank you,

David Emerson

I posted this video because it is an oncologist giving what I consider to be a fair, pros and cons, assessment of ivermectin as a cancer therapy.

Ivermectin to Treat Cancer? Get the FACTS

Research on ivermectin and breast cancer is mostly preclinical (cells/animals). It’s intriguing as a “drug repurposing” idea, but there’s no good clinical evidence yet that ivermectin treats breast cancer in people, and at least one breast cancer trial pathway has been withdrawn.

What the lab (preclinical) research shows

1) Direct anti-cancer effects in breast-cancer models

Several studies report that ivermectin can reduce breast-cancer cell growth and affect pathways linked with survival and spread:

  • PAK1–AKT–mTOR / autophagy (cell + mouse models): ivermectin inhibited breast-cancer growth and induced “cytostatic” autophagy in preclinical work.
  • Cancer stem-like cells: ivermectin preferentially inhibited breast cancer “stem-like” subpopulations and reduced expression of stemness genes in lab models.
  • Apoptosis + reduced migration: ivermectin reduced proliferation and migration and induced apoptosis markers in breast-cancer cells in vitro (reported in a breast-cancer signaling paper referencing ivermectin as a PAK1 inhibitor).

2) Anti-metastasis / EMT and Wnt signaling

Wnt/β-catenin signaling is often implicated in invasion, EMT, and resistance phenotypes.

  • In endocrine-resistant breast-cancer cell lines, ivermectin inhibited EMT-related behavior and Wnt-pathway features tied to invasion/metastasis.
  • Separately, ivermectin has been shown to inhibit Wnt/β-catenin–related metastasis signaling in cancer models (not exclusively breast), which is often cited as a plausible mechanism for anti-motility effects.
  • A mechanistic paper identifies TELO2 as a mammalian target linked to ivermectin’s Wnt/β-catenin repression (mechanism-focused, not breast-only).

3) Immune effects that could (in theory) help immunotherapy

A notable mouse-model study reported that ivermectin can promote immunogenic cancer cell death and increase T-cell infiltration into breast tumors, suggesting a possible rationale for combining ivermectin with checkpoint inhibitors.

What human research says (clinical evidence)

Human data in breast cancer are very limited and mostly in the form of trials/abstracts rather than definitive outcomes.

  • An NCI-listed phase II trial of ivermectin + pembrolizumab for metastatic triple-negative breast cancer is shown as “withdrawn.”
  • There are trial listings/abstract pages describing ivermectin combined with checkpoint inhibitors (e.g., balstilimab), but publicly available sources don’t (yet) establish clear efficacy outcomes in routine care.

Bottom line: Ivermectin is not an evidence-based breast cancer treatment at this time; it remains investigational.

A key practical issue: lab doses vs. achievable human exposure

Many breast-cancer cell studies use micromolar ivermectin concentrations. With typical approved oral dosing, reported peak blood levels are far lower (for example, one human PK paper reports ~50 ng/mL Cmax after 12 mg, which is in the tens of ng/mL range).
This “exposure gap” is one reason promising in-vitro effects often don’t translate into effective, safe cancer therapy.

Safety and interaction considerations (important if someone is considering off-label use)

Ivermectin is generally well-tolerated at antiparasitic doses, but adverse effects and drug–drug interactions matter—especially in oncology, where polypharmacy is common.

  • FDA prescribing information (Stromectol) details warnings/adverse reactions.
  • A review of human pharmacokinetics/interactions summarizes metabolism/interaction considerations.
  • Post-marketing analyses discuss neurologic adverse events (rare but important), especially in certain contexts.

Effects on Tumor Migration

Studies show ivermectin may reduce:

  • tumor cell invasion
  • migration
  • metastatic signaling

This effect may involve suppression of epithelial-mesenchymal transition (EMT).

Wnt Signaling

Wnt signaling promotes metastatic spread in breast cancer.

Ivermectin appears to inhibit this pathway.

PubMed
https://pubmed.ncbi.nlm.nih.gov/36381328/

Ivermectin and Immunotherapy

Immune Activation

Ivermectin may stimulate immune activity against tumors by activating P2X7 receptors.

This signaling pathway can trigger:

  • tumor cell death
  • immune activation

Study
https://www.nature.com/articles/srep16222

Combination Therapy

Some animal studies suggest ivermectin may improve responses to:

  • immune checkpoint inhibitors
  • PD-1 therapies
  • These findings are preliminary but intriguing.

To Learn More About Repurposed Drugs for Cancer-

PubMed links to key breast-cancer–relevant papers

Leave a Comment:

Popular posts

Multiple Myeloma Diet
 Multiple Myeloma Multiple Myeloma Diet
Feb 15, 2022
Multiple Myeloma Survivor- A Different kind of Second Opinion-
 Multiple Myeloma
Nov 04, 2022
C-B-D Enhances Velcade (BORT)
 integrative therapy Multiple Myeloma
Aug 07, 2022
Are Endometrial Polyps Overtreated?
 pre-cancer
Nov 14, 2021